Notas del episodio
This week, we have two interviews: one to mark Childhood Cancer Awareness Month, on osteosarcoma with Paul Romness from OS Therapies; and IMUNON’s CEO, Stacy Lindborg, talking about ovarian cancer, immunotherapy, covid, and more.
Interview times:
02:33 OS Therapies
23:03 IMUNON
Challenging osteosarcoma
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialisation of treatments for osteosarcoma (OS) and other solid tumours. OST-HER2, the company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein ...
Palabras clave
biotechbiotechnologycancerimmunotherapyIMUNONOS Therapies